Mangafodipir trisodium 0.5mmol/50ml solution for infusion vials
Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas.
Safety information for pregnancy and breastfeeding
Pregnancy
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Mangafodipir
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Trials: 2 · 1995–2026
Showing the 50 most relevant studies, sorted by most relevant.
Luis Martí‐Bonmatí, Amura Fog, Bart Op de Beeck, et al.
European Radiology, 2003
- Contrast Media
- Edetic Acid
- Magnetic Resonance Imaging
Jérôme Alexandre, Carole Nicco, Christiane Chéreau, et al.
JNCI Journal of the National Cancer Institute, 2006
- Oxaliplatin
- Antineoplastic Combined Chemotherapy Protocols
- Catalase
Wolfgang Schima, R. Függer, Ewald Schober, et al.
American Journal of Roentgenology, 2002
- Contrast Media
- Magnetic Resonance Imaging
- Adenocarcinoma
Takamichi Murakami, R L Baron, Mark S. Peterson, et al.
Radiology, 1996
- Contrast Media
- Magnetic Resonance Imaging
- Edetic Acid
B. Yeh, R. Breiman, B. Taouli, et al.
Radiology, 2004
- Contrast Media
- Bile Ducts
- Cholangiography
D. Sahani, S. Kalva, A. Fischman, et al.
AJR. American journal of roentgenology, 2005
- Adenocarcinoma
- Colonic Neoplasms
- Contrast Media
Matthijs Oudkerk, Carl G. Torres, Bin Song, et al.
Radiology, 2002
- Magnetic Resonance Imaging
- Contrast Media
- Diagnosis, Differential
W. Schima, R. Függer
European Radiology, 2002
- Contrast Media
- Edetic Acid
- Laparotomy
N. Rofsky, J. Earls
Magnetic resonance imaging clinics of North America, 1996
Juan Sanchez‐Ramos, Shijie Song, Xiaoyuan Kong, et al.
Journal of Drug Delivery Science and Technology, 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
20 minutes
Mechanism
After intravenous administration, the chelate dissociates slowly to manganese an…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
20 minutes
[L874]
Protein binding
27%
[L874]…
Volume of distribution
1.5 l/kg
Metabolism
Elimination
24 hours
Clearance
3.1 mL/min
[A19709]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 732 interactions
Mangafodipir displays embryotoxic and fetotoxic potential thus is contradindicated in pregnant patients. It is not reported to be genotoxic .
[L875]
LD50 in the mouse is 5 mmol/kg .
[A19718]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L874]
[L874]
Manganese is transported to the liver via α2-macroglobulin and to a lesser extent, albumin .
[A19708]
[L874]
Fodipir is distributed rapidly throughout the body with the highest concentrations in the kidneys, lung, blood and liver with a low affinity in the myocardium and brain. Manganese is initially distributed to the kindeys and sequentially to liver, spleen and pancreas .
[L875]
[L874]
Corresponsing zinc compounds are ZnDPDP, ZnDPMP and ZnPLED .
[A19708]
Manganese is released from the complex to be transported to target organs.
[L875]
[A19709]
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:17109629 PMID:17293870 PMID:22736759 PMID:25326704 PMID:25491917
Selectively transports various divalent metal cations, in decreasing affinity: Cd(2+) > Fe(2+) > Co(2+), Mn(2+) >> Zn(2+), Ni(2+), VO(2+) .
PMID:17109629 PMID:17293870 PMID:22736759 PMID:25326704 PMID:25491917
Essential for maintenance of iron homeostasis by modulating intestinal absorption of dietary Fe(2+) and TF-associated endosomal Fe(2+) transport in erythroid precursors and other cells (By similarity). Enables Fe(2+) and Mn(2+) ion entry into mitochondria, and is thus expected to promote mitochondrial heme synthesis, iron-sulfur cluster biogenesis and antioxidant defense (By similarity) .
PMID:24448823
Can mediate uncoupled fluxes of either protons or metal ions
Proteins that carry this drug through the body
The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region, a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
ATC V08CA05
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Mangafodipir
Additional database identifiers
Drugs Product Database (DPD)
11970
ChemSpider
32700460
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11180
GeneCards
SOD2
UniProt Accession
SODM_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7
GenAtlas
A2M
GeneCards
A2M
GenBank Gene Database
M11313
GenBank Protein Database
177870
UniProt Accession
A2MG_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:399
GenAtlas
ALB
GeneCards
ALB
GenBank Gene Database
V00494
GenBank Protein Database
28590
UniProt Accession
ALBU_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10908
GeneCards
SLC11A2
Guide to Pharmacology
967
UniProt Accession
NRAM2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q423624), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.